GlobalData on MSN1d
Zealand and Roche strike $5.3bn obesity treatment deal
The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.
Medscape8d
Immune System the Missing Link in Blood Glucose Control?
Portuguese researchers identified a type of immune cell that appears to travel to the pancreas to stimulate glucagon ...
GlobalData on MSN10d
AbbVie enters obesity space with $2.3bn Gubra deal
AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...
Tyla10d
What you need to know about Mounjaro after Scott Disick admits to using it
Kourtney Kardashian's ex, Scott Disick, admitted to using Mounjaro on a recent episode of The Kardashians which hit our ...
Pharmabiz14d
Biocon introduces glucagon-like peptide-1, Liraglutide in United Kingdom
Liraglutide in United Kingdom: Our Bureau, Bengaluru Friday, February 28, 2025, 15:30 Hrs [IST] Biocon Limited, an innovation-led global ...
Medical Xpress18d
Study finds GLP-1 receptor agonists target fat over muscle for weight loss
They function by mimicking the action of GLP-1 hormone, which plays a crucial role in stimulating insulin secretion, inhibiting glucagon secretion, and delaying gastric emptying to suppress ...
Medical Dialogues13d
Biocon launches Liraglutide for diabetes, obesity in UK
Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, ...
Healthline29d
Is Zepbound Covered by Medicare?
When these hormones are activated, they slow stomach emptying and reduce glucagon secretion. Glucagon is a hormone involved in appetite and blood sugar regulation. This could help you to lose ...